A phase I study of 99mTc-hR3 (DiaCIM), a humanized immunoconjugate directed towards the epidermal growth factor receptor. (Nuclear medicine communications, 2002)

(untitled) - Vallis, K; Reilly, R; Chen, P; Oza, A; Hendler, A; Cameron, R; Hershkop, M; Iznaga-Escobar, N; Ramos-Suzarte, M; Keane, P